ライフサイエンスコーパス: Sjogren syndrome

1 , the term 'Sjogren disease' should replace 'Sjogren syndrome'.

2 ed often-undiagnosed systemic disease (e.g., Sjogren syndrome).

3 tients with a history of physician-diagnosed Sjogren syndrome.

4 arthritis, systemic lupus erythematosus and Sjogren syndrome.

5 ents with severe DED who were diagnosed with Sjogren syndrome.

6 both the dystroglycanopathies and Marinesco-Sjogren syndrome.

7 d systemic autoimmunity resembling lupus and Sjogren syndrome.

8 Cs) from lacrimal glands of a mouse model of Sjogren syndrome.

9 e diseases, including systemic sclerosis and Sjogren syndrome.

10 rrelated with other diagnostic components of Sjogren syndrome.

11 se in a neurodegenerative model of Marinesco-Sjogren syndrome.

12 ted in several autoimmune disorders, such as Sjogren syndrome.

13 a diagnosis of lupus erythematosus and 1 had Sjogren syndrome.

14 nvolved in cystic fibrosis, pancreatitis, or Sjogren syndrome.

15 targets, which may be relevant for childhood Sjogren syndrome.

16 ollowing targeted head and neck radiation or Sjogren syndrome.

17 at of other disorders, including colitis and Sjogren syndrome.

18 tory diseases such as acute pancreatitis and Sjogren syndrome.

19 ment of patients with acute pancreatitis and Sjogren syndrome.

20 nitis and are a model for the human disorder Sjogren syndrome.

21 ients with pulmonary complications of RA and Sjogren syndrome.

22 ulcerative colitis), psoriasis, and primary Sjogren syndrome.

23 wn some benefit in rheumatoid vasculitis and Sjogren syndrome.

24 sms responsible for tear film instability in Sjogren syndrome.

25 rimal gland inflammation that is a model for Sjogren syndrome.

26 various infectious agents in both lupus and Sjogren syndrome.

27 ti-exocrine gland pathology similar to human Sjogren syndrome.

28 tal lupus, systemic lupus erythematosus, and Sjogren syndrome.

29 ts had primary amyloidosis, including 5 with Sjogren syndrome, 1 with rheumatoid arthritis, and 1 wit

30 ses were Stevens-Johnson syndrome (22 eyes), Sjogren syndrome (11 eyes), graft-vs-host disease (2 eye

31 ommon indication for implantation was severe Sjogren syndrome (33.3%) followed by graft-versus-host d

32 2008 to May 2011, 120 patients with primary Sjogren syndrome according to American-European Consensu

33 f neurological conditions, such as Marinesco-Sjogren syndrome and Borna virus infection, which result

34 A patient with Sjogren syndrome and features of AD-HIES with this mutat

35 scusses difficulties in diagnosing childhood Sjogren syndrome and highlights recent findings in Sjogr

36 tentially lower disease activity in SLE with Sjogren syndrome and in SSc with Sjogren syndrome than i

37 pe, which clinically overlaps with Marinesco-Sjogren syndrome and INPP5K disease.

38 ic profiling on cells derived from Marinesco-Sjogren syndrome and INPP5K patients and identified alte

39 ankylosing spondylitis, systemic sclerosis, Sjogren syndrome and osteoarthritis, mounting evidence i

40 mechanisms involved in the manifestations of Sjogren syndrome and rheumatoid arthritis.

41 toid arthritis, psoriatic arthritis, primary Sjogren syndrome and systemic lupus erythematosus.

42 owing the clinical overlap between Marinesco-Sjogren syndrome and the INPP5K phenotype.

43 oman with a history of rheumatoid arthritis, Sjogren syndrome, and hypertension presented with a head

44 ient with a history of rheumatoid arthritis, Sjogren syndrome, and hypertension presented with headac

45 rature include a dry eye syndrome similar to Sjogren syndrome, and ischemic retinopathy caused by eit

46 of important genetic modifiers of Marinesco-Sjogren syndrome, and provide additional pathways for th

47 risks for lung cancer, rheumatoid arthritis, Sjogren syndrome, and Raynaud syndrome.

48 Having positive anti-Sjogren syndrome antigen A antibody was associated with

49 duce de novo synthesis of LAMB1 protein in a Sjogren syndrome antigen B (La/SSB)-dependent manner in

50 al siRNA that targets endogenously expressed Sjogren syndrome antigen B (Ssb) mRNA, indicating that o

51 Here, we identify Sjogren syndrome antigen B (SSB)/La as a pre-miRNA-bindi

52 ineutrophil cvtoplasmic antibody (or cANCA), Sjogren syndrome antigens A and B (SS-A and SS-B, respec

53 lysis was negative for antinuclear antibody, Sjogren syndrome antigens A and B, cytoplasmic antineutr

54 s, the prevalence and prognosis of childhood Sjogren syndrome are unknown, in part due to lack of chi

55 es, such as systemic lupus erythematosus and Sjogren syndrome, are linked with an upregulation of IFN

56 e, we uncover a molecular mechanism by which Sjogren syndrome-associated autoantigen (SSA), an estrog

57 so found in the conjunctiva of patients with Sjogren syndrome at the gene and protein levels.

58 tear deficiency (ATD), Sjogren syndrome, non-Sjogren syndrome ATD, and control subjects.

59 ritis, systemic lupus erythematosus, primary Sjogren syndrome, autoimmune vesiculobullous skin diseas

60 umatoid factor; 6.25% SS-A/SS-B; 31.3% early Sjogren syndrome biomarkers; 6.25% ANA-positive/RF-negat

61 ly higher incidence of rheumatoid arthritis, Sjogren syndrome, celiac disease, type I diabetes mellit

62 worse corneal epithelial disease in ATD and Sjogren syndrome, conditions with lacrimal gland dysfunc

63 osus, inflammatory bowel disease, psoriasis, Sjogren syndrome, coronary artery disease, multiple scle

64 y reduced in the tear fluid of patients with Sjogren syndrome, corroborating mRNA data obtained using

65 ased risk of developing psoriatic arthritis, Sjogren syndrome, Crohn disease, vitiligo, alopecia area

66 y (rheumatoid arthritis; lupus; scleroderma; Sjogren Syndrome; dermatomyositis/polymyositis; unspecif

67 tment for systemic scleroderma and secondary Sjogren syndrome developed fever during tapering of ster

68 n side effect of head and neck radiotherapy, Sjogren syndrome, diabetes, old age, and numerous medica

69 I, 1.8-25.5; P = .005), higher ESSDAI (EULAR Sjogren Syndrome Disease Activity Index) scores (median

70 levated levels of IL-1beta, as they occur in Sjogren syndrome exocrine glands, may impair the secreto

71 m; P = .0057), ATD (210 mum; P = .0016), and Sjogren syndrome groups (171 mum; P = .0054).

72 il1 gene have been associated with Marinesco-Sjogren syndrome, hallmarks of which include ataxia and

73 Nomenclature for the disease widely known as Sjogren syndrome has proven unsatisfactory.

74 The tear fluid of patients with Sjogren syndrome has reduced levels of the goblet cell-s

75 ative abundance of MUC mRNA in patients with Sjogren syndrome in relation to that of normal subjects.

76 seases like systemic lupus erythematosus and Sjogrens syndrome in humans.

77 Sjogren syndrome is a chronic autoimmune disease affecti

78 Sjogren syndrome is a phenotypically varied autoimmune d

79 Childhood Sjogren syndrome is a poorly defined and underdiagnosed

80 Marinesco-Sjogren syndrome is a rare human disorder caused by bial

81 Primary Sjogren syndrome is a systemic autoimmune disease charac

82 The pathogenesis of Sjogren syndrome is emerging, including roles of T and B

83 Whether mortality in primary Sjogren syndrome is increased compared with that of the

84 Although primary Sjogren syndrome is typically considered a disease of mi

85 IL-10 partially suppressed the appearance of Sjogren-syndrome-like features of reduced tear productio

86 In CTDs associated with Sjogren syndrome, lymphoma risk seems higher than that o

87 dry eye) more often agreed that living with Sjogren syndrome made every day a challenge (adjusted od

88 DED signs were associated significantly with Sjogren syndrome (mean composite signs severity score 0.

89 ession was found in experimental dry eye and Sjogren syndrome models and was GC specific.

90 Marinesco-Sjogren syndrome (MSS) is an autosomal recessive, neurod

91 and mutations in this gene lead to Marinesco-Sjogren syndrome (MSS), a debilitating autosomal recessi

92 us erythematosus, antiphospholipid syndrome, Sjogren syndrome, myasthenia gravis, and celiac disease.

93 f normal subjects (n = 17) and patients with Sjogren syndrome (n = 11) after instillation of 60 micro

94 isease (MGD), aqueous tear deficiency (ATD), Sjogren syndrome, non-Sjogren syndrome ATD, and control

95 seases such as systemic lupus erythematosus, Sjogren syndrome or Behcet disease and granulomatous dis

96 une disorder that can occur alone in primary Sjogren syndrome or in association with other connective

97 p = 0.003), Raynaud syndrome (p = 0.023) and Sjogren syndrome (p = 0.044) were significantly associat

98 Specific recent notable findings in Sjogren syndrome pathogenesis include identification of

99 Total of 163 consecutive primary Sjogren syndrome patients evaluated between January 2007

100 decreased in the conjunctival epithelium of Sjogren syndrome patients with dry eye and decreased gob

101 I interferon signature in salivary glands of Sjogren syndrome patients, characterization of salivary

102 Primary Sjogren syndrome (pSS) is an autoimmune disorder charact

103 e is involved in the pathogenesis of primary Sjogren syndrome (pSS), but whether the signature is typ

104 Systemic lupus erythematosus and Sjogren syndrome remain elusive in the description of th

105 ses, including systemic lupus erythematosus, Sjogren syndrome, rheumatoid arthritis and multiple scle

106 ns of EBV with systemic lupus erythematosus, Sjogren syndrome, rheumatoid arthritis and multiple scle

107 ssociated with different diseases, including Sjogren syndrome, sialadenitis, and iatrogenic disease,

108 pression cytology performed on control eyes, Sjogren syndrome (SS) ATD, and non-SS ATD was stained wi

109 ffects of intestinal dysbiosis in a model of Sjogren syndrome (SS) by subjecting mice to desiccating

110 nic sialadenitis, and SG fibrosis and lacked Sjogren syndrome (SS) characteristic autoantibodies.

111 neck cancers or from the autoimmune disease Sjogren syndrome (SS) frequently result in the reduction

112 e probes show prominent IFN-gamma effects in Sjogren syndrome (SS) tissues.

113 Sjogren syndrome (SS), the second most common autoimmune

114 cy [n = 10]-without (n = 7) and with (n = 3) Sjogren syndrome (SS)-and conjunctivochalasis [n = 12])

115 une and immune-related conditions, including Sjogren syndrome (SS); immune checkpoint inhibitor-induc

116 implants are associated with higher rates of Sjogren syndrome (Standardized incidence ratio [SIR]8.14

117 rma, thyroiditis, primary biliary cirrhosis, Sjogren syndrome, systemic lupus, dermatomyositis, and n

118 in SLE with Sjogren syndrome and in SSc with Sjogren syndrome than in SLE or SSc alone.

119 Among patients with primary Sjogren syndrome, the use of hydroxychloroquine compared

120 In Sjogren syndrome, there appears to be a change in the rh

121 n syndrome and highlights recent findings in Sjogren syndrome treatment and pathogenesis from studies

122 stimation of the prevalence and incidence of Sjogren syndrome varies depending on diagnostic criteria

123 g spondylitis, systemic lupus erythematosus, Sjogren syndrome, vitiligo, alopecia areata, and multipl

124 ASDs, including alopecia areata, Sjogren syndrome, vitiligo, cutaneous lupus erythematosu

125 the conjunctival epithelium of patients with Sjogren syndrome was significantly lower than in normal

126 Among ASD subtypes, alopecia areata and Sjogren syndrome were consistently associated with lower

127 implications for the human ataxia Marinesco-Sjogren syndrome, where it is interesting to speculate t

128 mab show some therapeutic potential in adult Sjogren syndrome, whereas newer modalities including gen